Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab – An attention may be required

BACKGROUND: C-reactive protein (CRP) is a marker of inflammation and infection. The main proinflammatory cytokine that leads to CRP gene expression is IL-6. The study aimed to compare CRP level between patients who were treated with Tocilizumab (TCZ), an il-6 receptor blocker, and other advanced ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Berman, Mark, Berliner, Shlomo, Bashouti, Nancy, Elkayam, Ori, Ziv-Baran, Tomer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245240/
https://www.ncbi.nlm.nih.gov/pubmed/37292345
http://dx.doi.org/10.1016/j.heliyon.2023.e16665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10245240/
https://www.ncbi.nlm.nih.gov/pubmed/37292345
http://dx.doi.org/10.1016/j.heliyon.2023.e16665

Ejemplares similares